• Dr. Yang received her M.D. degree and PhD degree in China. She completed postdoctoral training and was appointed as an Assistant Professor in the Department of Pathology, University of Arkansas for Medical Sciences. Dr. Yang joined the faculty of Department of Pathology at UAB in 2006. She is currently an Associate Professor and Principal Investigator in the Division of Molecular and Cellular Pathology.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2022 Runx2 Deficiency in Osteoblasts Promotes Myeloma Resistance to Bortezomib by Increasing TSP-1–Dependent TGFβ1 Activation and Suppressing Immunity in Bone MarrowMolecular Cancer Therapeutics.  21:347-358. 2022
    2020 Runx2 deficiency in osteoblasts promotes myeloma progression by altering the bone microenvironment at new bone sitesCancer Research.  80:1036-1048. 2020
    2018 Runx2 suppression by miR-342 and miR-363 inhibits multiple myeloma progressionMolecular Cancer Research.  16:1138-1148. 2018
    2016 Adipocyte-Lineage Cells Support Growth and Dissemination of Multiple Myeloma in BoneAmerican Journal of Pathology.  186:3054-3063. 2016
    2016 Syndecan-1 (CD138) suppresses apoptosis in multiple myeloma by activating IGF1 receptor: Prevention by synstatinIGF1R inhibits tumor growthCancer Research.  76:4981-4993. 2016
    2016 Matricellular proteins as regulators of cancer metastasis to boneMatrix Biology.  52-54:301-314. 2016
    2016 Inhibition of transforming growth factor-β activation diminishes tumor progression and osteolytic bone disease in mouse models of multiple myelomaAmerican Journal of Pathology.  186:678-690. 2016
    2016 Heparanase promotes myeloma progression by inducing mesenchymal features and motility of myeloma cellsOncotarget.  7:11299-11309. 2016
    2015 The growth and aggressive behavior of human osteosarcoma is regulated by a CaMKII-controlled autocrine VEGF signaling mechanismPLoS One.  10. 2015
    2015 Loss of Runx2 in committed osteoblasts impairs postnatal skeletogenesisJournal of Bone and Mineral Research.  30:71-82. 2015
    2015 Myeloma cell-derived Runx2 promotes myeloma progression in boneBlood.  125:3598-3608. 2015
    2013 Heparanase inhibits osteoblastogenesis and shifts bone marrow progenitor cell fate in myeloma bone diseaseBone.  57:10-17. 2013
    2011 SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axisClinical Cancer Research.  17:1382-1393. 2011
    2011 Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activityJournal of Biological Chemistry.  286:6490-6499. 2011
    2010 Heparanase enhances local and systemic osteolysis in multiple myeloma by upregulating the expression and secretion of RANKLCancer Research.  70:8329-8338. 2010
    2009 Syndecan-1 is required for robust growth, vascularization, and metastasis of myeloma tumors in vivoJournal of Biological Chemistry.  284:26085-26095. 2009
    2008 Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myelomaJournal of Biological Chemistry.  283:32628-32636. 2008
    2008 Syndecan-1: A dynamic regulator of the myeloma microenvironmentClinical and Experimental Metastasis.  25:149-159. 2008
    2007 The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapyBlood.  110:2041-2048. 2007
    2007 Heparanase enhances syndecan-1 shedding: A novel mechanism for stimulation of tumor growth and metastasisJournal of Biological Chemistry.  282:13326-13333. 2007
    2005 HSulf-1 and HSulf-2 are potent inhibitors of myeloma tumor growth in vivoJournal of Biological Chemistry.  280:40066-40073. 2005
    2005 Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: Growth regulation and the prospect of new cancer therapiesJournal of Cellular Biochemistry.  96:897-905. 2005
    2005 Identification of an invasion regulatory domain within the core protein of syndecan-1Journal of Biological Chemistry.  280:3467-3473. 2005
    2005 Heparanase promotes the spontaneous metastasis of myeloma cells to boneBlood.  105:1303-1309. 2005
    2005 Dynamic remodeling of syndecan-1 structure regulates myeloma tumor growth and metastasis in vivoTrends in glycoscience and glycotechnology : TIGG.  17:263-270. 2005
    2004 Heparan sulfate proteoglycans and heparanase - Partners in osteolytic tumor growth and metastasisMatrix Biology.  23:341-352. 2004
    2003 High Heparanase Activity in Multiple Myeloma Is Associated with Elevated Microvessel DensityCancer Research.  63:8749-8756. 2003
    2003 Heparan sulfate regulates targeting of syndecan-1 to a functional domain on the cell surfaceJournal of Biological Chemistry.  278:12888-12893. 2003
    2002 Soluble syndecan-1 promotes growth of myeloma tumors in vivoBlood.  100:610-617. 2002
    2002 Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cellsBlood.  99:1745-1757. 2002


    Year Title Altmetric
    2010 Proteoglycans and cancer.  191-215. 2010

    Education And Training

  • Doctor of Philosophy Level Degree in Medicine, 1990
  • Doctor of Medicine, China Medical University 1983
  • Full Name

  • Yang Yang